How tariffs are reshaping the US pharmaceutical industry

President Trump’s broad 10% tariff push spares pharma for now, but global supply chains may not stay immune.

When the storm hits, the worst course of action is to cling to the past, replaying “what ifs,” panicking over what should have been done, or wishing the winds would simply pass. Crises demand clarity, not nostalgia.

The first step is to see things exactly as they are: without illusion,

Free Trial

Register for free to keep reading.

To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.

  • Unlimited access to industry insights
  • Stay on top of key rules and regulatory changes with our Rules Navigator
  • Ad-free experience with no distractions
  • Regular podcasts from trusted external experts
  • Fresh compliance and regulatory content every day
Register for free Already a member? Sign in